{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(8)"],"submitter":["Gligorov J"],"pubmed_abstract":["Background
The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting. The choice of adjuvant treatments might vary considerably in different countries according to various treatment guidelines. This prospective multicenter study is the first to assess the impact of the Oncotype DX assay in the French clinical setting.Methods
A total of 100 patients with ER+, human epidermal growth factor receptor 2-negative EBC, and node-negative (pN0) disease or micrometastases in up to 3 lymph nodes (pN1mi) were enrolled. Treatment recommendations, physicians' confidence before and after knowing the Recurrence Score value, and physicians' percept"],"journal":["The oncologist"],"pagination":["873-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4524752"],"repository":["biostudies-literature"],"pubmed_title":["Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study."],"pmcid":["PMC4524752"],"pubmed_authors":["Sautiere JL","Gligorov J","Misset JL","Largillier R","Rouzier R","Rouanet P","de Roquancourt A","Pivot XB","Jacot W","Penault-Llorca FM","Pomel C","Francilian Breast Intergroup","Naman HL","Spaeth D"],"additional_accession":[]},"is_claimable":false,"name":"Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.","description":"Background
The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting. The choice of adjuvant treatments might vary considerably in different countries according to various treatment guidelines. This prospective multicenter study is the first to assess the impact of the Oncotype DX assay in the French clinical setting.Methods
A total of 100 patients with ER+, human epidermal growth factor receptor 2-negative EBC, and node-negative (pN0) disease or micrometastases in up to 3 lymph nodes (pN1mi) were enrolled. Treatment recommendations, physicians' confidence before and after knowing the Recurrence Score value, and physicians' percept","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Aug","modification":"2025-04-19T21:34:29.934Z","creation":"2019-03-27T01:56:15Z"},"accession":"S-EPMC4524752","cross_references":{"pubmed":["26112003"],"doi":["10.1634/theoncologist.2014-0467"]}}